Back

Introduction

01

AMD Worldwide

Macular Degeneration Prevalence

AMD is the most common cause of irreversible blindness in both developed and developing countries, particularly in people older than 60 years. AMD is more common in women than men and people of Caucasian and Chinese ethnicity are more likely to be affected by the disease. Approximately 30 million humans are affected by the disease, around 90% of these have the dry, or non-exudative form of AMD. Two-thirds of patients with advanced AMD and visual acuity of 0.3 or less are pseudophakic - these patients can benefit from the SML.

TREATMENT OF AMD

There have been significant advances in the treatment of exudative (wet) AMD with the introduction of anti-angiogenesis therapy, and patients now have effective treatment options that can prevent blindness and, in many cases, restore their vision.
02

Clinical Evidence

0 COUNTRIES
0 PATIENTS
0 EYE IMPLANTED IN TOTAL

SAFE IMPLANTATION AND EFFICIENT VISUAL ENHANCEMENT

    • No intra- or postoperative complications during the first year following implantation
    • Efficient preoperative testing protocol that helps in predicting the visual outcomes, and in selecting the patients that would benefit from SML-implantation
    • Predictable surgical outcomes
    • Significant improvement of near vision, visual function and quality of life
    • Preserved distance vision and stable intraocular pressure
    • Preserved visual field
    • Post-surgical eye training further improves the visual outcomes
Please note: If indications are set properly and patients are trained appropriately after surgery, results are good or excellent.
    • 01
      Srinivasan S. Implantation of Scharioth macula lens in patients with age-related macular degeneration: results of a prospective European multicentre clinical trial
      BMJ Open Ophthalmol. 2019 Jul 7;4(1):e000322. doi: 10.1136/bmjophth-2019-000322. eCollection 2019.
    • 02
      Scharioth GB. New add-on intraocular lens for patients with age-related macular degeneration.
      J Cataract refract Surg. 2015; 41:1559-63.
    • 03
      Nekolová J, Rozsíval P, Sin M, Jiraskova N. Scharioth Macula Lens: A new intraocular implant for low-vision patients with stabilized maculopathy- first experience.
      Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Jun;161(2):206-209.
    • 04
      Reiter N, Werner L, Guan J, Li J, Tsaousis KT, Mamalis N, Srinivasan S. Assessment of a new hydrophilic acrylic supplementary IOL for sulcus fixation in pseudophakic cadaver eyes.
      Eye (Lond). 2017 May;31(5):802-809. doi: 10.1038/eye.2016.310. Epub 2017 Jan 20.
    • 05
      Bereczki Á. Experiences with the Scharioth Macula Lens - new hope for patients with dry macular degeneration.
      Rom J Ophthalmol. 2019 Apr-Jun;63(2):128-134.
03

SML History

THE SML IS A JOINT INNOVATION OF PROF. GÁBOR SCHARIOTH AND MEDICONTUR MEDICAL ENGINEERING, A MEDICAL DEVICE COMPANY WITH 30 YEARS OF FOCUSED EXPERIENCE WITH INTRAOCULAR IMPLANTS.

    • During my ophthalmological practice, macular diseases have always been my special concern, especially Age-related Macular Degeneration.

      I had to find again and again that patients evaluate treatment outcomes differently from us doctors. While a patient maintains their ability to focus and orientate themself, they are usually not able to read anymore.

      These observations finally led to the development of our Macula Lens in cooperation with the Hungarian company Medicontur Medical Engineering.

      Prof. Gábor B. Scharioth MD, PhD

    • Medicontur Medical Engineering is an independent European company that has been in existence since 1989. With more than 5 million intraocular implants inserted across 60 countries, we have been at the forefront of developing innovative IOL solutions with a focus on high-quality material, design and optics. Our concept is to provide ophthalmologists with the one best option for their patients.

      The SML project gives AMD patients the chance to regain their lost abilities and to improve their quality of life. This is something that we, together with Prof. Gábor Scharioth, are very proud of. The first SML was implanted in 2013, and since then multiple clinics worldwide have included this novel solution into their practice.

      Alexandra Kontur MD, PhD, Scientific Director
    ​